Give us a call 215-275-1556

The epidemic of opioid lawsuits continues to pick-up steam.  The latest case is the State of Washington’s latest suit against Johnson & Johnson (“J&J”).  It, in part, targets J&J’s active pharmaceutical ingredient (“API”) business.  Once again,  API manufacturing is in the spotlight.  To read about the case and its potential impacts, check out my article at Policy & Medicine.